SIC
VRTX icon

Salem Investment Counselors’s Vertex Pharmaceuticals VRTX Stock Holding History

Salem Investment Counselors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Hold
494
– – 0.01% 378
2026
Q1 		$221K Hold
494
– – 0.01% 369
2025
Q4 		$224K Buy
494
+135
+38% +$58.2K 0.01% 364
2025
Q3 		$141K Sell
359
-135
-27% -$56.4K ﹤0.01% 413
2025
Q2 		$220K Buy
494
+174
+54% +$80.2K 0.01% 357
2025
Q1 		$155K Buy
320
+61
+24% +$28.4K 0.01% 386
2024
Q4 		$104K Hold
259
– – ﹤0.01% 450
2024
Q3 		$120K Hold
259
– – ﹤0.01% 430
2024
Q2 		$121K Buy
259
+1
+0.4% +$434 ﹤0.01% 419
2024
Q1 		$108K Hold
258
– – ﹤0.01% 439
2023
Q4 		$105K Sell
258
-2
-0.8% -$739 ﹤0.01% 433
2023
Q3 		$90.4K Buy
260
+2
+0.8% +$699 ﹤0.01% 431
2023
Q2 		$90.8K Hold
258
– – ﹤0.01% 433
2023
Q1 		$81.3K Buy
258
+58
+29% +$17.4K ﹤0.01% 450
2022
Q4 		$57.8K Hold
200
– – ﹤0.01% 494
2022
Q3 		$58K Buy
+200
New +$57.5K ﹤0.01% 458
2022
Q1 		– Sell
-1,861
Closed -$409K – 1113
2021
Q4 		$409K Buy
1,861
+22
+1% +$4.28K 0.01% 292
2021
Q3 		$334K Sell
1,839
-2
-0.1% -$390 0.02% 286
2021
Q2 		$371K Buy
1,841
+1,839
+91,950% +$385K 0.02% 270
2021
Q1 		$0 Sell
2
-17
-89% -$3.73K ﹤0.01% 927
2020
Q4 		$4K Buy
+19
New +$4.36K ﹤0.01% 728
2019
Q3 		– Sell
-209
Closed -$38K – 669
2019
Q2 		$38K Sell
209
-1,690
-89% -$295K ﹤0.01% 407
2019
Q1 		$366K Buy
1,899
+5
+0.3% +$924 0.04% 170
2018
Q4 		$314K Sell
1,894
-5
-0.3% -$866 0.04% 164
2018
Q3 		$366K Sell
1,899
-235
-11% -$41.8K 0.04% 170
2018
Q2 		$363K Hold
2,134
– – 0.03% 168
2018
Q1 		$335K Hold
2,134
– – 0.04% 173
2017
Q4 		$320K Buy
2,134
+50
+2% +$7.4K 0.03% 179
2017
Q3 		$316K Buy
2,084
+1,870
+874% +$281K 0.04% 177
2017
Q2 		$28K Buy
+214
New +$25.8K ﹤0.01% 373

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Salem Investment Counselors's VRTX Position: Q2 2026 in Review

Salem Investment Counselors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 494 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #378.

Salem Investment Counselors first reported a position in VRTX in Q2 2017 and has held it in 30 quarters since. The position peaked at $409K in Q4 2021. 843 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Salem Investment Counselors held 494 shares of Vertex Pharmaceuticals worth $245K as of Q2 2026.
  • Salem Investment Counselors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #378 holding.
  • Salem Investment Counselors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
  • Salem Investment Counselors's Vertex Pharmaceuticals position peaked at $409K in Q4 2021.
  • 843 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.